Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc; and with Rosalind Franklin University of Medicine and Science. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
IPO Year: 2018
Exchange: NASDAQ
Website: aptinyx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2022 | Outperform → Mkt Perform | William Blair | |
| 12/20/2021 | $12.00 → $10.00 | Outperform | SVB Leerink |
William Blair downgraded Aptinyx from Outperform to Mkt Perform
SVB Leerink reiterated coverage of Aptinyx with a rating of Outperform and set a new price target of $10.00 from $12.00 previously
JP Morgan downgraded Aptinyx from Neutral to Underweight
8-K - Aptinyx Inc. (0001674365) (Filer)
8-K - Aptinyx Inc. (0001674365) (Filer)
25-NSE - Aptinyx Inc. (0001674365) (Subject)
8-K - Aptinyx Inc. (0001674365) (Filer)
DEF 14A - Aptinyx Inc. (0001674365) (Filer)
S-8 POS - Aptinyx Inc. (0001674365) (Filer)
RW - Aptinyx Inc. (0001674365) (Filer)
S-8 POS - Aptinyx Inc. (0001674365) (Filer)
S-8 POS - Aptinyx Inc. (0001674365) (Filer)
S-8 POS - Aptinyx Inc. (0001674365) (Filer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company’s current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020. “We are thrilled to have Andy expand his role as president and chief operating officer, given his strong commitment to our company, scientific acumen, and proven track record of success,” said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. “Aptinyx is well-positioned to continue to build a leading neuro
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi
NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET. A live webcast of the fireside chat will be available to view on the "Events and Presentations" page in the "Investors & Media" section of Aptinyx's website at https://ir.aptinyx.com and will be archived on Aptinyx's website for 30 days following the event. About Aptinyx Aptinyx Inc. is a clinical-stage biopharm
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the 52nd Annual Meeting of the Society for Neuroscience being held November 12-16, 2022 in San Diego, CA. The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic stress disorder and opioid use disorder. The poster presentations will be available on the Publications page of the company's website at www.aptinyx.com. NYX-783 Presentation Details: Presentation Title: Positive allosteric modula
Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor
NIH HEAL Initiative grant, administered by NIDA, funds preclinical and clinical studies of NYX-783 in opioid use disorder Preclinical studies demonstrate NYX-783 has promising activity and safety profile relevant to treatment of opioid use disorder, clearing path for funding and initiation of clinical evaluation Phase 1 clinical study in individuals using opioids expected to begin later this year Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEA
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'
Results from the Phase 2 study are expected in 1Q 2023 Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment of 99 patients in the company's ongoing Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Patients recently enrolled in the study are completing the 12-week treatment period and 30-day safety follow-up period. The company expects to report results from the study in 1Q 2023. "The completion of enrollment in our Phase 2 study of NYX-458 is a significant milestone for
NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. NYX-2925 did not achieve statistically significant separation from placebo on the study's primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12. "We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in thi
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13G - Aptinyx Inc. (0001674365) (Subject)
Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'
Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902 (international) and refer to conference ID 4855909. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Apt
Current cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout from exploratory Phase 2 study of NYX-458 in cognitive impairment expected in late 2022 or 1Q 2023 Data readout from Phase 2b study of NYX-783 50 mg in PTSD expected in 2H 2023 Conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2022 and highlighted re
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022 at 5:00 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (international) and refer to conference ID 305649. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx
Data readouts from Phase 2b studies of NYX-2925 in painful DPN and fibromyalgia expected in April 2022 and early to mid 3Q 2022, respectively Ongoing Phase 2 study in cognitive impairment expected to read out in late 2022 or 1Q 2023 Initiated Phase 2b study of NYX-783 50 mg in PTSD in 4Q 2021; Phase 2b study of NYX-783 150 mg in PTSD expected to commence in early 2Q 2022 Balance sheet expected to fund R&D and operations through mid 2023 Conference call today at 5:00 p.m. EDT Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth qu
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 23, 2022 at 5:00 p.m. ET to report fourth quarter and full year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200-6205 (domestic) or (929) 526-1599 (international) and refer to conference ID 768426. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be a
Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022 PTSD Phase 2b program is set to initiate in 4Q 2021 Strong balance sheet supports Phase 2 data readouts from all four clinical development programs Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 20
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights. To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599 (international) and refer to conference ID 322632. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Apti